{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:25:38Z","timestamp":1774459538852,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1987,6,1]],"date-time":"1987-06-01T00:00:00Z","timestamp":549504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1987,6,1]],"date-time":"1987-06-01T00:00:00Z","timestamp":549504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1987,6]]},"DOI":"10.1007\/bf00203545","type":"journal-article","created":{"date-parts":[[2004,8,31]],"date-time":"2004-08-31T07:22:31Z","timestamp":1093936951000},"page":"187-198","source":"Crossref","is-referenced-by-count":25,"title":["Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors"],"prefix":"10.1007","volume":"5","author":[{"given":"Charles L.","family":"Vogel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Gorowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Davila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Eisenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Kosinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram P.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niramol","family":"Savaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00203545_CR1","first-page":"465","volume":"62","author":"EP Flannery","year":"1978","unstructured":"Flannery EP, Corder MP, Shehan TF, Pajak TF, Bateman JR: Phase II study of ICRF-159 in non-Hodgkin's lymphomas. Cancer Treat Rep 62:465\u2013467, 1978","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR2","first-page":"111","volume":"60","author":"CLM Olweny","year":"1976","unstructured":"Olweny CLM, Masaba JP, Sikenunda W, Toya T: Treatment of Kaposi's sarcoma with ICRF-159 (NSC-129943). Cancer Treat Rep 60:111\u2013113, 1976","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR3","first-page":"557","volume":"66","author":"MK Shah","year":"1982","unstructured":"Shah MK, Engstrom PF, Catalano RB, Paul AR, Bellet RE, Creech RH: Phase II trial of Razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy. Cancer Treat Rep 66:557\u2013558, 1982","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR4","first-page":"127","volume":"63","author":"MT Bakowski","year":"1979","unstructured":"Bakowski MT, Prentice HG, Lister TA, Malpas JS, McElwain TJ, Powles RL: Limited activity of ICRF-159 in advanced acute leukemia. Cancer Treat Rep 63:127\u2013129, 1979","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR5","first-page":"2085","volume":"63","author":"MT Bakowski","year":"1979","unstructured":"Bakowski MT, Brearley RL, Wrigley HM: Treatment of blast cell crisis of chronic myeloid leukemia with ICRF-159 (Razoxane). Cancer Treat Rep 63:2085\u20132087, 1979","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR6","first-page":"111","volume":"63","author":"RH Creech","year":"1979","unstructured":"Creech RH, Engstrom PF, Harris D, Catalano RB, Bellet RE: Phase II study of ICRF-159 in refractory metastatic breast cancer. Cancer Treat Rep 63:111\u2013114, 1979","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR7","first-page":"1395","volume":"60","author":"RE Bellet","year":"1976","unstructured":"Bellet RE, Engstrom PF, Catalano RB, Creech RH, Mastrangelo MJ: Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. Cancer Treat Rep 60:1395\u20131397, 1976","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR8","first-page":"543","volume":"69","author":"HO Douglass Jr","year":"1985","unstructured":"Douglass HO Jr, MacIntyre JM, Kaufman J, vonHoff D, Engstrom PF, Klaassen D: Eastern Cooperative Oncology Group Phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi 64, piperazinedione, and Lomustine. Cancer Treat Rep 69:543\u2013545, 1985","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR9","first-page":"1047","volume":"64","author":"AR Paul","year":"1980","unstructured":"Paul AR, Catalano RB, Engstrom PF: Phase III study of ICRF-159 vs. 5-FU in the treatment of advanced metastatic colorectal carcinoma. Cancer Treat Rep 64:1047\u20131049, 1980","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR10","first-page":"103","volume":"20","author":"DF Chiuten","year":"1979","unstructured":"Chiuten DF, Vogl SE, Kaplan BH: Combination chemotherapy of advanced colorectal cancer with Triazinate and ICRF-159 after failure of 5-fluorouracil (Abstract). Proc Am Assoc Cancer Res 20:103, 1979","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00203545_CR11","first-page":"1143","volume":"64","author":"SE Vogl","year":"1980","unstructured":"Vogl SE, Qazi R, Berenzwieg M: Combination chemotherapy for advanced colorectal cancer with triazinate, ICRF-159, 5-fluorouracil, and methyl-CCNU. Cancer Treat Rep 64:1143\u20131145, 1980","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR12","first-page":"761","volume":"59","author":"TA Marciniak","year":"1975","unstructured":"Marciniak TA, Moertel CG, Schutt AJ: Phase II study of ICRF-159 (NSC-129943) in advanced colorectal cancer. Cancer Chemother Rep 59:761\u2013763, 1975","journal-title":"Cancer Chemother Rep"},{"key":"BF00203545_CR13","first-page":"713","volume":"69","author":"Gastrointestinal Tumor Study Group","year":"1985","unstructured":"Gastrointestinal Tumor Study Group: Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane and beta-2\u2032-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Cancer Treat Rep 69:713\u2013716, 1985","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR14","first-page":"151","volume":"62","author":"DL Ahmann","year":"1978","unstructured":"Ahmann DL, Edmonson S, Frytak LK, Kuols LK, Bisel HF, Rubin J: Phase II study of ICRF-159 versus combination cis-DDP and DTIC in patients with disseminated malignant melanoma. Cancer Treat Rep 62:151\u2013153, 1978","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR15","first-page":"1397","volume":"63","author":"PG Dyment","year":"1979","unstructured":"Dyment PG, Starling K, Land V: Razoxane (ICRF-159) in the treatment of pediatric solid tumors. Cancer Treat Rep 63:1397\u20131398, 1979","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR16","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/1097-0142(197410)34:4<1040::AID-CNCR2820340413>3.0.CO;2-5","volume":"34","author":"RD Ryall","year":"1974","unstructured":"Ryall RD, Hanham WF, Newton A, Hellman K, Brinkley DM, Hjertaas OK: Combined treatment of soft tissue and osteosarcomas by radiation and ICRF-159. Cancer 34:1040\u20131045, 1974","journal-title":"Cancer"},{"key":"BF00203545_CR17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/1097-0142(197909)44:3<891::AID-CNCR2820440315>3.0.CO;2-R","volume":"44","author":"RD Ryall","year":"1979","unstructured":"Ryall RD, Bates T, Newton KA, Hellman K: Combination of radiotherapy and ICRF-159 for chondrosarcoma. Cancer 44:891\u2013895, 1979","journal-title":"Cancer"},{"key":"BF00203545_CR18","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/1097-0142(19840501)53:9<1852::AID-CNCR2820530910>3.0.CO;2-F","volume":"53","author":"MP Corder","year":"1984","unstructured":"Corder MP, Tewfik HH, Clamon GH, Platz CE, Leimert JT, Herbst KD, Byfield JE: Radiotherapy plus Razoxane for advanced limited extent carcinoma of the lung. Cancer 53:1852\u20131856, 1984","journal-title":"Cancer 53"},{"key":"BF00203545_CR19","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/222384a0","volume":"222","author":"AM Creighton","year":"1969","unstructured":"Creighton AM, Hellman K, Whitecross S: Antitumor activity of a series of bisdiketopiperazines. Nature 222:384\u2013395, 1969","journal-title":"Nature"},{"key":"BF00203545_CR20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/bmj.4.5731.344","volume":"4","author":"PJ Salsbury","year":"1970","unstructured":"Salsbury PJ, Burrage K, Hellman K: Inhibition of metastatic spread by ICRF-159: Selective depletion of a metastatic characteristic. Br Med J 4:344\u2013346, 1970","journal-title":"Br Med J"},{"key":"BF00203545_CR21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/224273a0","volume":"224","author":"K Hellman","year":"1969","unstructured":"Hellman K, Burrage K: Control of malignant metastases by ICRF-159. Nature 224:273\u2013275, 1969","journal-title":"Nature"},{"key":"BF00203545_CR22","first-page":"839","volume":"34","author":"SE James","year":"1974","unstructured":"James SE, Salsbury AJ: Effect of (\u00b1)-1,2-Bis(3,5-dioxopiperazin-1-yl) propane on tumor blood vessels and its relationship to the antimetastatic effect in the Lewis lung carcinoma. Cancer Res 34:839\u2013842, 1974","journal-title":"Cancer Res"},{"key":"BF00203545_CR23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0014-2964(75)90068-7","volume":"11","author":"A Atherton","year":"1975","unstructured":"Atherton A: The effect of (\u00b1)1,2-bis(3,5-dioxopiperazin1-yl) propane (ICRF-159) on liver metastases from a hamster lymphoma. Eur J Cancer 11:383\u2013388, 1975","journal-title":"Eur J Cancer"},{"key":"BF00203545_CR24","first-page":"62","volume":"13","author":"MV Buin","year":"1975","unstructured":"Buin MV, Baldwin RW: Influence of ICRF-159 and Triton, W.R. 1339 on metastases of a rat epithelioma. Br J Cancer 13:62\u201367, 1975","journal-title":"Br J Cancer"},{"key":"BF00203545_CR25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0041-008X(74)90031-3","volume":"27","author":"ELH Herman","year":"1974","unstructured":"Herman ELH, Mhatre RM, Chadwick DP: Modification of some of the toxic effects of daunomycin by pretreatment with ICRF-159. Toxicol Appl Pharmacol 27:517\u2013526, 1974","journal-title":"Toxicol Appl Pharmacol"},{"key":"BF00203545_CR26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3181\/00379727-140-36432","volume":"140","author":"EH Herman","year":"1972","unstructured":"Herman EH, Mhatre RM, Lee IP, Waravdekar VS: Prevenion of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart (36432). Proc Soc Exp Biol Med 140:234\u2013239, 1972","journal-title":"Proc Soc Exp Biol Med"},{"key":"BF00203545_CR27","first-page":"689","volume":"59","author":"RJ Woodman","year":"1975","unstructured":"Woodman RJ, Cysyk RL, Kline I, Gang M, Venditti JM: Enhancement of the effectiveness of daunorubicin (NSC 82151) or adriamycin (NSC 123127) against early mouse L1210 leukemia with ICRF-159 (NSC 129943). Cancer Chemother Rep 59:689\u2013695, 1975","journal-title":"Cancer Chemother Rep"},{"key":"BF00203545_CR28","first-page":"189","volume":"15","author":"GL Wampler","year":"1974","unstructured":"Wampler GL, Speckhart V, Regelson W: Phase I clinical study of adriamycin ICRF-159 combination and other drug combinations (Abstract). Proc Am Assoc Cancer Res 15:189, 1974","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00203545_CR29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/1097-0142(197410)34:4<1033::AID-CNCR2820340412>3.0.CO;2-0","volume":"34","author":"K Hellman","year":"1974","unstructured":"Hellman K, Murkin GE: Synergism of ICRF-159 and radiotherapy in treatment of experimental tumors. Cancer 34:1033\u20131039, 1974","journal-title":"Cancer"},{"key":"BF00203545_CR30","first-page":"143","volume":"4","author":"DS Poster","year":"1981","unstructured":"Poster DS, Penta JS, Bruno S, Macdonald JS: ICRF-187 in clinical oncology. Cancer Clin Trials 4:143\u2013146, 1981","journal-title":"Cancer Clin Trials"},{"key":"BF00203545_CR31","first-page":"89","volume":"63","author":"E Herman","year":"1979","unstructured":"Herman E, Ardalan B, Bier C, Waravdekar V, Krop S: Reduction of daunomycin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian Golden hamsters. Cancer Treat Rep 63:89\u201392, 1979","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR32","first-page":"1211","volume":"64","author":"BS Levine","year":"1980","unstructured":"Levine BS, Henry MC, Port CD, Rosen E: Preclinical toxicologic evaluation of ICRF-187 in dogs. Cancer Treat Rep 64:1211\u20131215, 1980","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ijc.2910050107","volume":"5","author":"AM Creighton","year":"1970","unstructured":"Creighton AM, Birnie GD: Biochemical studies on growth-nhibitory bisdioxopiperazines. I. Effect on DNA, RNA and protein synthesis in mouse-embryo fibroblast. Int J Cancer 5:47\u201354, 1970","journal-title":"Int J Cancer"},{"key":"BF00203545_CR34","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/226524a0","volume":"226","author":"HBA Sharpe","year":"1970","unstructured":"Sharpe HBA, Field FO, Hellman K: Mode of action of the cytostatic agent \u2018ICRF-159\u2019. Nature 226:524\u2013526, 1970","journal-title":"Nature"},{"key":"BF00203545_CR35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00177411","volume":"1","author":"RH Wheeler","year":"1983","unstructured":"Wheeler RH, Clauw DJ, Natale RB, Ruddon RW: The cytokinetic and cytotoxic effects of ICRF-159 and ICRF-187 in vitro and ICRF-187 in human bone marrow in vivo. Invest New Drugs 1:283\u2013295, 1983","journal-title":"Invest New Drugs"},{"key":"BF00203545_CR36","first-page":"539","volume":"44","author":"K Hellman","year":"1970","unstructured":"Hellman K, Field FO: Effect of ICRF-159 on the mammalian cell cycle: Significance for its use in cancer chemotherapy. J Natl Cancer Inst 44:539\u2013543, 1970","journal-title":"J Natl Cancer Inst"},{"key":"BF00203545_CR37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.1.5800.597","volume":"1","author":"AW LeServe","year":"1972","unstructured":"LeServe AW, Hellman K: Metastases and the normalization of tumor blood vessels by ICRF-159: A new type of drug action. Br Med J 1:597\u2013601, 1972","journal-title":"Br Med J"},{"key":"BF00203545_CR38","first-page":"459","volume":"65","author":"JM Koeller","year":"1981","unstructured":"Koeller JM, Earhart RH, Davis HL: Phase I trial of ICRF-187 by 48 hours continuous infusion. Cancer Treat Rep 65:459\u2013463, 1981","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR39","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/1097-0142(19810415)47:8<1959::AID-CNCR2820470808>3.0.CO;2-X","volume":"47","author":"J Liesmann","year":"1981","unstructured":"Liesmann J, Belt R, Haas C, Hoogstraten B: Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy. Cancer 47:1959\u20131962, 1981","journal-title":"Cancer"},{"key":"BF00203545_CR40","first-page":"249","volume":"65","author":"DD Von Hoff","year":"1981","unstructured":"VonHoff DD, Howser D, Lewis BJ, Holcenberg J, Weiss RB, Young RC: Phase I study of ICRF-187 using a daily for 3 days schedule. Cancer Treat Rep 65:249\u2013252, 1981","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR41","first-page":"703","volume":"70","author":"JS Holcenberg","year":"1986","unstructured":"Holcenberg JS, Tutsch KD, Earhart RH, Ungerleider RS, Kamen BS, Pratt CB, Gribble TJ, Glaubiger DL: Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rep 70:703\u2013709, 1986","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR42","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.2042-7158.1975.tb10247.x","volume":"27","author":"PJ Creaven","year":"1975","unstructured":"Creaven PJ, Allen LM, Alford DA: The bioavailability in man of ICRF-159 \u2014 A new oral antineoplastic agent. J Pharm Pharmacol 27:914\u2013918, 1975","journal-title":"J Pharm Pharmacol"},{"key":"BF00203545_CR43","first-page":"393","volume":"58","author":"PJ Creaven","year":"1974","unstructured":"Creaven PJ, Cohen MH, Hansen HH, Selawry OS, Taylor SG: Phase 1 clinical trial of a single dose and two weekly schedules of ICRF-159 (NSC-129943). Cancer Chemother Rep 58:393\u2013400, 1974","journal-title":"Cancer Chemother Rep"},{"key":"BF00203545_CR44","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.2042-7158.1975.tb10247.x","volume":"27","author":"PJ Creaven","year":"1975","unstructured":"Creaven PJ, Allen LM, Alford DA: The bioavailability in man of ICRF-159, a new oral antineoplastic agent. J Pharm Pharmacol 27:914\u2013918, 1975","journal-title":"J Pharm Pharmacol"},{"key":"BF00203545_CR45","first-page":"1355","volume":"64","author":"MO O'Connell","year":"1980","unstructured":"O'Connell MO, Begg CB, Silverstein MN, Glick JH, Oken MM: Randomized clinical trial comparing two dose regiments of ICRF-159 in refractory malignant lymphomas. Cancer Treat Rep 64:1355\u20131358, 1980","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR46","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/jps.2600640623","volume":"64","author":"W Sadee","year":"1975","unstructured":"Sadee W, Starosoik J, Finn C, Cohen J: Determination of (+)-1,2-Bis(3\u20135-dioxopiperazinyl) propane plasma levels in rats, rabbits, and humans by GLC and mass fragmentography. J Pharm Sci 64:998\u20131001, 1975","journal-title":"J Pharm Sci"},{"key":"BF00203545_CR47","first-page":"5255","volume":"42","author":"RH Earhart","year":"1982","unstructured":"Earhart RH, Tutsch KD, Koeller JM, Rodriguez R, Robins HI, Vogel CL, Davis HL, Tormey DC: Pharmacokinetics of (\u00b1)-1,2-Di(3,5-dioxopiperazin-1-yl) propane intravenous infusion in adult cancer patients. Cancer Res 42:5255\u20135261, 1982","journal-title":"Cancer Res"},{"key":"BF00203545_CR48","first-page":"311","volume":"67","author":"RB Natale","year":"1983","unstructured":"Natale RB, Wheeler RH, Liepman MK, Sauder A, Bricker L: Phase II trial of ICRF-187 in non-small cell lung cancer. Cancer Treat Rep 67:311\u2013313, 1983","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR49","first-page":"427","volume":"68","author":"RH Wheeler","year":"1984","unstructured":"Wheeler RH, Bricker LJ, Natale RB, Baker SR: A phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck. Cancer Treat Rep 68:427\u2013428, 1984","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR50","first-page":"184","volume":"27","author":"M Arora","year":"1986","unstructured":"Arora M, Pazdur R, Samson M, Kinzie J, Baker L: ICRF-187 (NSC-168780): A phase II evaluation in metastatic colorectal carcinoma (Abstract). Proc Am Assoc Cancer Res 27:184, 1986","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00203545_CR51","first-page":"915","volume":"70","author":"LH Brubaker","year":"1986","unstructured":"Brubaker LH, Vogel CL, Einhorn LH, Birch R: Treatment of advanced adenocarcinoma of the kidney with ICRF-187 (NSC 169780); a Southeastern Cancer Study group trial. Cancer Treat Rep 70:915\u2013916, 1986","journal-title":"Cancer Treat Rep"},{"key":"BF00203545_CR52","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(81)91361-1","volume":"2","author":"R Joshi","year":"1981","unstructured":"Joshi R, Smith B, Phillips RH, Barrett AJ: Acute myelomonocytic leukemia after Razoxane therapy. Lancet 2:1343\u20131344, 1981","journal-title":"Lancet"},{"key":"BF00203545_CR53","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0140-6736(84)90330-1","volume":"2","author":"S Lakhani","year":"1984","unstructured":"Lakhani S, Davidson RN, Hiwaizi F, Marsden RA: Razoxane and leukemia. Lancet 2:288\u2013289, 1984","journal-title":"Lancet"},{"key":"BF00203545_CR54","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2133.1983.tb00549.x","volume":"109","author":"IJ Horton","year":"1983","unstructured":"Horton IJ, MacDonald DM, Wells RS: Epitheliomas in patients receiving Razoxane therapy for psoriasis. Br J Derm 109:675\u2013678, 1983","journal-title":"Br J Derm"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00203545.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00203545\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00203545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00203545.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T17:38:04Z","timestamp":1678556284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00203545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,6]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1987,6]]}},"alternative-id":["BF00203545"],"URL":"https:\/\/doi.org\/10.1007\/bf00203545","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,6]]}}}